Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer

John D. Hainsworth, Nathan Levitan, Galen L. Wampler, Chandra Belani, Mahmoud S. Seyedsadr, J. Randolph, Lee P. Schacter, F. Anthony Greco

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Purpose: This randomized phase II study evaluated the efficacy and toxicity of etoposide phosphate when used in combination with cisplatin in the treatment of small-cell lung cancer. Patients and Methods: Patients with previously untreated small-cell lung cancer were randomized to receive cisplatin in combination with either etoposide or etoposide phosphate. Molar- equivalent doses of etoposide and etoposide phosphate were used. Response rate, time to progression, survival, and toxicity were compared. Results: Major response rates with etoposide phosphate and etoposide were 61% (95% confidence interval, 55% to 67%) and 58% (95% confidence interval, 52% to 64%), respectively (P = .85). No significant differences in median time to progression or survival were observed in patients who received etoposide phosphate versus etoposide. Grade 3 and 4 leukopenia occurred in 63% of patients who received etoposide phosphate compared with 77% who received etoposide (P = .16). Conclusion: The combination of etoposide phosphate an cisplatin is effective in the treatment of small-cell lung cancer, and can be administered with acceptable toxicity. Although this study was not designed to be a formal comparative trial, the efficacy and toxicity observed with this regimen were found to be similar to a standard etoposide/cisplatin regimen, using molar-equivalent etoposide doses. Because of its greater ease of administration, etoposide phosphate is preferable to etoposide for routine clinical use.

Original languageEnglish (US)
Pages (from-to)1436-1442
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number6
DOIs
StatePublished - Jun 1995

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Hainsworth, J. D., Levitan, N., Wampler, G. L., Belani, C., Seyedsadr, M. S., Randolph, J., Schacter, L. P., & Greco, F. A. (1995). Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. Journal of Clinical Oncology, 13(6), 1436-1442. https://doi.org/10.1200/JCO.1995.13.6.1436